Finance
UK's Alliance Pharma accepts DBAY's sweetened final offer
Published by Global Banking & Finance Review®
Posted on March 10, 2025
1 min readLast updated: January 24, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on March 10, 2025
1 min readLast updated: January 24, 2026
Alliance Pharma has accepted DBAY Advisors' final offer, valuing the company at £362M, a 46% premium over its January stock price.
(Reuters) -Britain's Alliance Pharma said on Monday it has agreed to a sweetened final cash proposal from asset management firm DBAY Advisors, valuing the healthcare group at about 362 million pounds ($467.5 million).
The revised 64.75 pence-per-share proposal is a 3.6% increase from the previous bid of 62.5 pence, and represents a premium of 46% to the Alliance stock's closing price on January 9, the day before the start of the offer period.
In January, the companies had agreed to the initial proposal of 62.5 pence, before the general meeting was adjourned in February to allow Alliance's shareholders additional time to consider the deal.
($1 = 0.7744 pounds)
(Reporting by Aby Jose Koilparambil and Raechel Thankam Job in Bengaluru; Editing by Mrigank Dhaniwala)
The final cash proposal from DBAY Advisors values Alliance Pharma at approximately 362 million pounds.
The revised offer of 64.75 pence per share is a 3.6% increase from the previous bid of 62.5 pence.
The new offer represents a premium of 46% to Alliance's stock's closing price on January 9.
The initial proposal of 62.5 pence was agreed upon in January before the general meeting was adjourned in February.
The report was authored by Aby Jose Koilparambil and Raechel Thankam Job in Bengaluru.
Explore more articles in the Finance category
